In The Field

Neuroscience 2008: New ‘epigenetic’ memory drug

Michael Ahlijanian, a vice-president of the small biotech company EnVivo, told the meeting that the company’s new compound EVP-0334 is to enter clinical trials for treating memory disorders ‘very soon’. That it has made it so far is surprising and scientifically interesting, particularly since it acts by interfering with epigenetic phenomena in the brain. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE